Multiple myeloma treatment in Istanbul, Turkey
Multiple myeloma is a cancer of the plasma cells in the bone marrow that can damage bones, kidneys and blood counts. It is usually treated with a combination of drugs — a proteasome inhibitor, an immunomodulatory drug and a corticosteroid given together — often followed by an autologous stem cell transplant for eligible patients, with monoclonal antibodies and, for relapsed disease, CAR T-cell therapy. Istanbul hospitals offer this full pathway, often at JCI-accredited, state-authorized centers and well below Western-European prices for the same protocol. Myeloma is generally treatable but relapsing, so care is usually continuous rather than a one-time cure. Every price we show is an illustrative placeholder until verified partner-hospital quotes exist — and you pay the hospital directly, never us. Start with a free 72-hour review of your reports before you decide anything.
What multiple myeloma is
The U.S. National Cancer Institute describes multiple myeloma as a cancer that begins in plasma cells, a type of white blood cell in the bone marrow. When these cells become malignant they crowd out healthy blood cells and produce an abnormal antibody, and the disease can damage the bones, kidneys and blood counts, causing bone pain or fractures, anemia, high calcium and kidney problems.
Diagnosis usually involves blood and urine tests that look for the abnormal M protein the myeloma cells make, a bone marrow biopsy to confirm and measure the plasma cells, and imaging to check the bones. Because myeloma behaves differently from a solid tumour and is generally treatable but relapsing, plans are built around continuing therapy rather than a single operation. Browse the wider cancer types hub for related diagnoses.
Treatment options
The modalities the NCI lists for multiple myeloma, and an honest note on each:
- Drug therapy combinations. The backbone of treatment — a proteasome inhibitor such as bortezomib, an immunomodulatory drug such as lenalidomide, and a corticosteroid are often given together. These drugs are priced per cycle, and cost scales with how many cycles you receive. How drug therapy is delivered →
- Targeted therapy and immunotherapy. Monoclonal antibodies such as daratumumab target the myeloma cells directly, and for disease that has relapsed the NCI describes CAR T-cell therapy and bispecific antibodies. Which applies is decided by your history, not a template. About targeted therapy →
- Autologous stem cell transplant. For eligible patients, high-dose therapy is followed by a transplant of the patient's own collected stem cells to rebuild the marrow. Eligibility depends on age, kidney function and fitness. About stem cell transplant →
- Supportive care and radiation. Because myeloma damages bones and kidneys, supportive care matters — bisphosphonates to protect the bones, measures to protect kidney function, and radiation to relieve a painful bone lesion. This runs alongside the main treatment, not instead of it.
See how these modalities work in general on the treatments & technology hub. Myeloma is generally treatable but relapsing, so care is often continuous, with maintenance therapy after the main plan rather than a one-time cure.
What it costs
There is no single myeloma price, because care is continuous rather than a one-time procedure — the cost is driven by which drugs are combined, how many cycles are given, whether an autologous stem cell transplant is part of the plan, and whether newer options such as monoclonal antibodies or cellular therapy are used, all of which are priced per cycle or per course and can dominate the total. Every figure OncologyIstanbul™ publishes today is an illustrative placeholder pending verified partner-hospital quotes, and each is itemized so you can hold a real quote up against it line by line. See the Turkey Oncology Price Index or the full cancer treatment cost in Turkey breakdown.
The hospital, verified
We don’t show a wall of smiling doctors or a “ranked” list — those are the easiest things to fabricate. Instead, you’re matched to one state-authorized Istanbul partner hospital whose hematology and stem cell transplant subspecialty fits your diagnosis, and you can verify its authorization against the Republic of Turkey Ministry of Health’s own records and its JCI accreditation in JCI’s public directory before you commit. Named specialist profiles appear only when a verified, consented physician is behind the name. See the full guide to cancer hospitals in Istanbul and how to check one yourself.
Where this fits
This is one diagnosis within the broader cancer treatment in Istanbul pillar. If you want your own reports read first, a free second opinion organizes and verifies your blood work, bone marrow report and imaging into a plain-language case file in your language before you decide whether to travel.
Check everything here — us included
Common questions
Can I get multiple myeloma treatment in Turkey?
Yes. Istanbul hospitals provide the full myeloma pathway the U.S. National Cancer Institute describes — drug-combination therapy that pairs a proteasome inhibitor such as bortezomib with an immunomodulatory drug such as lenalidomide and a corticosteroid, monoclonal antibodies such as daratumumab, high-dose therapy with an autologous stem cell transplant for eligible patients, and supportive care for the bones and kidneys myeloma can damage. Many centers hold JCI accreditation and Turkish Ministry of Health state authorization, both of which you can check yourself before you commit. The honest first step is a free case review of your blood work, bone marrow report and imaging so the plan is understood before you travel.
What does the drug-combination and transplant pathway look like?
Per the NCI, initial treatment for many patients is a combination of drugs given together — commonly a proteasome inhibitor such as bortezomib, an immunomodulatory drug such as lenalidomide, and a corticosteroid, sometimes with a monoclonal antibody added. For patients who are eligible, this induction phase is often followed by high-dose therapy and an autologous stem cell transplant, which uses the patient's own collected stem cells to rebuild the marrow. Maintenance drug therapy then usually continues afterward. Which parts of this pathway fit your case depends on age, kidney function and fitness, and a case review will flag what your reports establish so far.
Is CAR T-cell therapy available for relapsed myeloma?
The NCI describes CAR T-cell therapy and bispecific antibodies as options for multiple myeloma that has come back or stopped responding to earlier treatment (relapsed or refractory disease). These are complex cellular and immune therapies delivered at specialized centers, not first-line treatment for everyone, and eligibility depends on your prior treatments and overall health. Availability of any specific cellular therapy in Istanbul should be confirmed for your case rather than assumed. A free case review can flag whether your history points toward these options and what questions to put to a treating team. This is general information, not a treatment recommendation.
How much does multiple myeloma treatment cost in Istanbul?
There is no single figure, because myeloma care is continuous rather than a one-time procedure — the cost is driven by which drugs are combined, how many cycles are given, whether an autologous stem cell transplant is part of the plan, and whether newer options such as monoclonal antibodies or cellular therapy are used, all of which are priced per cycle or per course and can dominate the total. Istanbul typically runs well below Western-European prices for the same protocol, but every figure OncologyIstanbul™ publishes today is an illustrative placeholder pending verified partner-hospital quotes, itemized so you can check a real written quote line by line. See the Turkey Oncology Price Index for current ranges.
Start with a free 72-hour case review
Send your blood work, bone marrow report and imaging. Get a verified case file in your language — free, confidential, no obligation.
This page is general information, not medical advice. Medical facts are grounded in the U.S. National Cancer Institute; prices shown are illustrative placeholders pending verified partner-hospital quotes, not offers. Every cancer case is individual; assessments are based on the reports you provide and do not replace in-person examination.